Related Experiment Video

Updated: Sep 30, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.6K

Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation

Andreas S Papazoglou1,2, Anastasios Kartas1, Dimitrios V Moysidis1

  • 1First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636, Thessaloniki, Greece.

Cardiovascular Diabetology
|March 15, 2022
PubMed

Insights

Diabetes mellitus (DM) increases atrial fibrillation (AF) risk and worsens its outcomes. Glycated hemoglobin monitoring may predict AF and related events, guiding better management of this common comorbidity.

Area of Science:

  • Cardiology
  • Endocrinology
  • Public Health

Background:

  • Atrial fibrillation (AF) and diabetes mellitus (DM) are prevalent, interconnected cardiovascular diseases.
  • DM is a known risk factor for AF development and exacerbates AF-related complications like stroke and mortality.
  • The precise pathogenic links between DM and AF require further elucidation.

Purpose of the Study:

  • To review current literature on the association between DM and AF.
  • To evaluate the predictive value of glycated hemoglobin (HbA1c) for AF and adverse cardiovascular events.
  • To assess anti-diabetic treatments in patients with AF and guide clinical decision-making.

Main Methods:

  • Comprehensive literature search on DM and AF comorbidity.
  • Analysis of studies investigating HbA1c in relation to AF incidence and outcomes.
  • Review of current anti-hyperglycemic therapies and their implications for AF management.

Main Results:

  • DM significantly increases the risk of developing AF and negatively impacts its clinical course.
  • Glycated hemoglobin levels show potential for predicting AF occurrence and related adverse events.
  • Evidence on optimal anti-hyperglycemic strategies for AF patients is evolving.

Conclusions:

  • DM is a critical factor in AF pathogenesis and prognosis.
  • HbA1c measurement is a valuable tool for risk stratification in patients with DM and AF.
  • Integrated management strategies are needed to address the complexities of comorbid DM and AF.

Keywords:
Atrial fibrillationComorbidityDiabetes mellitusGlycated hemoglobinHbA1c

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.9K
Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats05:12

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

3.4K

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
302
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
131
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
191
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
56
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
427